Berlin Cures to Evaluate BC 007, an Aptamer, in Patients for the Treatment of COVID-19
June 24, 2020 02:00 ET
|
Berlin Cures Holding AG
Berlin Cures to Evaluate BC 007, an Aptamer, in Patients for the Treatment of COVID-19 Phase II/III clinical trial is scheduled to start in the second half of 2020 Berlin, Germany – 24 June 2020 –...